A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

NCT05859217 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
NSCLC Stage IV
Metastatic NSCLC - Non-Small Cell Lung Cancer
Advanced NSCLC

Interventions

DRUG: Cabozantinib
DRUG: Atezolizumab

Sponsor

Jun Zhang, MD, PhD

Collaborators

[object Object]
[object Object]